Patients aged 18 and over with obsessive-compulsive symptoms, depressive illness, or phobic states may be prescribed Anafranil tablets. Anafranil works on neurotransmitter signalling involved in…
Patients aged 18 and over with obsessive-compulsive symptoms, depressive illness, or phobic states may be prescribed Anafranil tablets. Anafranil works on neurotransmitter signalling involved in mood, anxiety, and repetitive thoughts or behaviours. Its dose is decided individually according to age, other medicines, and health conditions.
Anafranil belongs to the tricyclic antidepressant group. Its active substance is clomipramine hydrochloride, which affects the handling of serotonin and noradrenaline between nerve cells. The medicine is prescribed for defined psychiatric conditions rather than for occasional sadness, everyday stress, or short-lived worry.
The licensed clinical uses of clomipramine include depressive illness, obsessional states, phobic states, and obsessive-compulsive disorder. The UK prescribing information also recognises specialist use in cataplexy associated with narcolepsy. The choice depends on the diagnosis, symptom pattern, previous treatment, and the patient’s physical health.
Obsessive-compulsive disorder involves unwanted intrusive thoughts, repetitive behaviours, or both. Anafranil may reduce the intensity and frequency of these symptoms, although improvement often develops gradually rather than after one or two tablets.
Depressive illness can involve low mood, loss of interest, sleep disturbance, slowed thinking, hopelessness, and changes in appetite. Anafranil may be selected when a prescriber considers a tricyclic approach suitable, including situations where a previous antidepressant has not provided enough benefit.
Phobic states involve disproportionate fear and avoidance linked to a specific situation, object, or social setting. Treatment is usually most useful when combined with structured psychological therapy, such as cognitive behavioural therapy.
Doctors may use clomipramine outside its main licensed indications for panic disorder, generalised anxiety symptoms, or selected chronic pain syndromes. These uses require an individual clinical assessment because the balance between benefit and adverse effects differs between conditions.
Clomipramine may also be considered as an adjunct for cataplexy in narcolepsy. Cataplexy causes sudden loss of muscle control while consciousness remains intact. Specialist supervision is needed because sleep disorders can coexist with other medicines that affect alertness.
Its active substance is clomipramine hydrochloride, which affects the handling of serotonin and noradrenaline between nerve cells.
Clomipramine blocks the reuptake of serotonin and noradrenaline in the central nervous system. Reuptake is the process by which a nerve cell removes a chemical messenger from the space between cells. Blocking that process leaves more neurotransmitter available for signalling.
Serotonin contributes to mood regulation, anxiety processing, impulse control, and repetitive behaviour circuits. Noradrenaline contributes to alertness, attention, motivation, and stress responses. The clinical effect does not come from a simple increase in one chemical; it develops through changes in neural communication over time.
Anafranil has a stronger serotonergic profile than many older tricyclic antidepressants. This helps explain its place in obsessive-compulsive disorder, while its additional noradrenergic action may support treatment of depressive symptoms.
The medicine also affects receptors involved in acetylcholine, histamine, and alpha-adrenergic signalling. Those secondary actions explain several unwanted effects, including dry mouth, constipation, blurred vision, dizziness, increased appetite, and sleepiness.
The dose of Anafranil is decided individually, taking age, other medicines, and health conditions into account. A prescriber may start with a lower amount and adjust it gradually after assessing benefit, sedation, blood pressure, heart rhythm, and other adverse effects.
Anafranil may be used for several weeks or longer, depending on the condition. Obsessive-compulsive symptoms often need sustained treatment, and a prescriber may continue therapy after improvement to reduce relapse risk.
Tablets should not be crushed, chewed, split, or altered unless the prescriber or dispensing pharmacist has specifically confirmed that the particular tablet can be divided. Altering a tablet can affect how it is swallowed and may make dose measurement less reliable.
| Treatment approach | Main pharmacological action | Practical limitation |
|---|---|---|
| Clomipramine | Strong serotonin reuptake inhibition with additional noradrenaline effects | Anticholinergic effects, sedation, and cardiovascular precautions |
| Selective serotonin reuptake inhibitor | Mainly increases serotonin availability | Nausea, sleep changes, sexual dysfunction, and withdrawal symptoms may occur |
| Other tricyclic antidepressant | Increases noradrenaline and/or serotonin signalling | Anticholinergic and cardiac effects can limit use |
Several practical errors can make treatment appear less helpful or less tolerable:
Monoamine oxidase inhibitors must not be combined with clomipramine because excessive monoamine activity can cause severe hypertension, hyperthermia, agitation, muscle rigidity, seizures, or serotonin syndrome. A clinically appropriate washout interval is required when changing between these treatments.
Fluoxetine and other serotonergic antidepressants can increase the risk of serotonin toxicity when combined with clomipramine. Fluoxetine also remains in the body for a prolonged period, so switching requires careful planning rather than a simple next-day substitution.
Other medicines that can raise interaction risk include tramadol, linezolid, lithium, triptans, certain antipsychotics, sedating antihistamines, medicines that prolong the QT interval, and drugs that lower the seizure threshold. Carbamazepine and some other enzyme-inducing medicines may reduce clomipramine exposure.
Alcohol, opioid pain medicines, sleeping tablets, and sedative medicines can add to drowsiness and impair coordination. Pregnancy and breastfeeding require an individual risk assessment because antidepressant exposure near delivery may affect the newborn.
Anafranil may not be suitable if you take or have recently taken an MAOI, have had a serious reaction to clomipramine or another tricyclic antidepressant, or have certain heart-rhythm problems. Tell the prescriber if you have mania, narrow-angle glaucoma, urinary retention, severe liver disease, or a seizure history. Pregnancy and breastfeeding also need an individual medical review.
Anafranil can cause drowsiness, dry mouth, constipation, blurred vision, sweating, dizziness, nausea, tremor, headache, and changes in appetite. These effects are linked to the medicine’s activity at several receptor systems, not only serotonin pathways.
Sedation may be strongest after treatment begins or after a dose increase. Some people feel mentally slowed, while others experience restlessness or difficulty sleeping. Avoid driving until you know how Anafranil affects concentration and reaction time.
Anticholinergic effects deserve practical attention. Constipation can become troublesome, blurred vision may affect reading or night driving, and difficulty passing urine can be serious in people with prostate enlargement or bladder outflow problems.
Seek urgent medical help for fainting, a sustained fast or irregular heartbeat, severe confusion, high fever with muscle stiffness, seizures, severe allergic swelling, or thoughts of self-harm. A sudden painful eye with blurred vision may indicate acute angle-closure glaucoma and needs urgent assessment.
Anafranil may affect sexual function, including reduced libido, delayed orgasm, or difficulty reaching orgasm. This effect can be embarrassing to mention, yet it is clinically relevant and may influence whether a person continues treatment.
In clinical practice, doctors usually set two targets: reduction of the core symptoms and preservation of everyday function. A person may notice better sleep or less physical anxiety before obsessive thoughts or depressed mood improve.
Prescribers commonly review treatment after dose changes rather than judging the medicine after a single day. They may ask about bowel function, urination, blurred vision, sexual side effects, faintness, suicidal thoughts, and changes in energy.
A patient who suddenly feels unusually energetic, needs very little sleep, talks rapidly, or becomes impulsive needs prompt clinical review. Those changes can indicate mood elevation rather than recovery. Mood can change quickly. Sleep needs may fall. Contact the prescriber promptly.
Anafranil can be useful when its serotonergic action matches the clinical problem, but its anticholinergic and cardiac burden means that monitoring matters. Older adults may be more sensitive to confusion, falls, constipation, urinary retention, and low blood pressure.
Anafranil tablets should be swallowed with water unless a prescriber or dispensing pharmacist has confirmed that a specific tablet can be divided. Crushing or chewing can make swallowing unpleasant and may interfere with accurate dosing. NHS medicines guidance published in 2024 advises that tablets should not be altered without checking the formulation and instructions. The MHRA also treats changes to tablet administration as a medicine-safety issue requiring product-specific advice.
Some effects, such as drowsiness, dry mouth, or nausea, may appear soon after treatment begins. Improvement in depression or obsessive-compulsive symptoms usually takes longer and may develop over several weeks. NICE guidance updated in 2022 describes antidepressant response as gradual and recommends review when benefit or tolerability is uncertain. A lack of immediate improvement is not a reason to take extra tablets.
Anafranil can cause reduced libido, delayed orgasm, difficulty reaching orgasm, or other sexual difficulties. The NHS described sexual dysfunction as a recognised issue with antidepressant treatment in its 2024 medicines information. The symptom may be temporary or may continue while treatment continues. Report it directly because dose adjustment or a planned treatment change may be possible.
Combining Anafranil with monoamine oxidase inhibitors is contraindicated because of the risk of severe toxicity. Other serotonergic medicines, including some antidepressants, tramadol, lithium, and certain migraine treatments, can also increase serotonin-syndrome risk. The MHRA product information supports careful review of every prescribed, over-the-counter, and herbal product. St John’s wort should not be started alongside Anafranil without clinical advice.
Alcohol can intensify drowsiness, dizziness, poor coordination, and impaired judgement caused by Anafranil. The NHS stated in 2024 that alcohol may worsen sleepiness with antidepressants, even when a person has previously tolerated the medicine. Avoid driving or hazardous work after combining the two. People taking other sedating medicines face a greater risk of excessive central nervous system depression.
Regular sleep, moderate physical activity, adequate fluids, and fibre-rich food can support daily functioning and reduce constipation. NICE guidance for depression, updated in 2022, includes physical activity and structured psychological treatment as useful parts of care alongside medicines. Limit habits that worsen sedation or dehydration, including heavy alcohol use and irregular sleep schedules. Exercise should be introduced gradually if dizziness, low blood pressure, or marked fatigue occurs.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 4 reviews
The first fortnight was uncomfortable because my mouth was dry and I felt sleepy after work. By the second month, the checking rituals were taking less time, although I still needed therapy alongside the tablets.
York The first fortnight; by the second month 23 Oct 2026My sleep improved before my mood did. Constipation was the main nuisance, and I had to change my routine. I did not increase the dose when the first week felt slow.
Plymouth The first week 29 Oct 2026The medicine reduced the background noise in my head, but standing up quickly made me light-headed. My prescriber reviewed my other tablets and adjusted the timing.
Stoke-on-Trent 30 Sept 2026I noticed less panic after several weeks, but sexual side effects affected my willingness to continue. The benefit was real, though the trade-off needed an honest discussion.
Middlesbrough Several weeks 6 Oct 2026
